Updated Diagnostic Criteria and Management of AGEP
The most recent European expert consensus (2024) provides the current standard for AGEP diagnosis and management, emphasizing a multidisciplinary approach with dermatologists, allergologists, and pharmacovigilance services, while the EuroSCAR validation scoring system remains the gold standard for diagnostic confirmation 1.
Diagnostic Criteria
Clinical Features Required for Diagnosis
The diagnosis of AGEP relies on the EuroSCAR validation score, which stratifies cases as definite, probable, or possible based on the following key features 1, 2:
Cardinal Clinical Characteristics:
- Pustules: Multiple (dozens to hundreds) sterile, non-follicular, small (1-5mm) punctate pustules on erythematous and edematous skin
- Distribution: Typically starts in intertriginous areas (axillae, groin, neck folds) and spreads rapidly to trunk and limbs
- Timing: Acute onset with pustule development within hours to days after drug exposure (median latency 1-11 days for antibiotics)
- Resolution: Spontaneous resolution within 15 days after drug withdrawal, followed by characteristic desquamation
- Fever: Present in most cases (>38°C)
- Facial edema: Common accompanying feature 2, 3
Laboratory Findings:
- Neutrophilic leukocytosis (>7000/mm³)
- Peripheral blood eosinophilia in approximately one-third of patients 3
Histopathological Criteria
Skin biopsy is essential and should be taken from an early pustular lesion 1:
Key histologic features:
- Spongiform subcorneal and/or intraepidermal pustules (most diagnostic feature)
- Pustules are non-follicular, large, contiguous, and tend to coalesce
- Papillary dermal edema
- Neutrophilic and eosinophilic infiltration in the dermis
- Perivascular infiltrate of lymphocytes and histiocytes 3, 4
Minimum Diagnostic Work-Up
Based on the 2024 European consensus 1:
Initial Assessment:
- Detailed drug history: Document all medications taken in the preceding 2 months, including over-the-counter drugs, with exact dates of initiation
- Physical examination: Map extent of pustules, erythema, and mucosal involvement (mild oral involvement occurs in 20-30% of cases)
- Skin biopsy: From early pustular lesion for routine histopathology
- Laboratory tests: Complete blood count with differential, liver and kidney function tests, electrolytes
- Bacterial cultures: From pustules to confirm sterility
- Photography: Document extent and morphology
Important Pitfall: AGEP can initially mimic toxic shock syndrome or other serious infections before pustules fully develop, particularly in the first 24-48 hours 5. Maintain high clinical suspicion when fever and diffuse erythema follow recent antibiotic exposure, even if pustules are not yet apparent.
Differential Diagnosis
- Pustular psoriasis (generalized pustular psoriasis)
- Staphylococcal scalded skin syndrome
- Generalized bullous fixed drug eruption
- Drug reaction with eosinophilia and systemic symptoms (DRESS)
- Stevens-Johnson syndrome/toxic epidermal necrolysis (early stages)
- Subcorneal pustular dermatosis
Key distinguishing feature: AGEP has rapid onset and resolution (within 15 days), whereas pustular psoriasis is chronic/relapsing and lacks the characteristic drug exposure timeline.
Management
Acute Phase Management
Immediate discontinuation of the culprit drug - This is the single most critical intervention and often sufficient for resolution
Supportive care:
- Hospitalization for severe cases with extensive skin involvement or systemic complications
- Fluid and electrolyte management
- Temperature control
- Skin care with emollients and antiseptic solutions
Topical corticosteroids:
- Potent topical steroids are recommended despite limited evidence 7
- Apply to affected areas to reduce inflammation and pruritus
- Widely used in clinical practice with good safety profile
Systemic corticosteroids:
- No strong evidence supports routine use, but widely employed in practice 1
- Consider for severe cases with extensive involvement or systemic complications
- Typical regimen: prednisone 0.5-1 mg/kg/day with rapid taper as pustules resolve
Avoid antibiotics unless secondary bacterial infection is documented 7 - pustules are sterile and antibiotics may worsen the reaction
Novel Treatment Option: For severe, refractory cases, IL-17 inhibitors (ixekizumab) show promise based on recent case reports demonstrating rapid improvement within 5 days 8. This represents an emerging therapeutic option when conventional management fails, though more data are needed.
Prognosis and Monitoring
- Mortality rate: approximately 5% 3
- Deaths typically occur in elderly patients with comorbidities or those with secondary infections
- Most cases resolve completely within 2 weeks without sequelae
- Drug rechallenge is absolutely contraindicated and associated with the most severe outcomes 3
Post-Acute Phase: Allergological Work-Up
Essential for preventing recurrence 1, 4:
Timing: Perform allergological testing at least 4-6 weeks after complete resolution to avoid false-negative results
Recommended tests:
Patch testing: Most valuable in-vivo test for identifying culprit drug
- Perform with suspected drug and chemically related compounds
- Positive in 50-70% of cases
In-vitro testing:
- Lymphocyte transformation test (LTT)
- Cytokine release assays (particularly IL-8/CXCL8)
- These complement patch testing when results are negative 4
Documentation: Report to pharmacovigilance services and provide patient with written documentation of drug allergy for future medical care 1
Cross-reactivity considerations: Patients with AGEP to one beta-lactam antibiotic may react to structurally related antibiotics; allergological evaluation should assess cross-reactivity patterns.
Follow-Up
- Clinical follow-up at 2-4 weeks to confirm complete resolution
- Allergological consultation for definitive testing
- Patient education on avoidance of culprit drug and cross-reactive medications
- Medical alert documentation for future healthcare encounters 1